

REMARKS/ARGUMENTS

The Pending Claims

Claims 36, 37, and 40-70 are pending and are directed to a bacterial artificial chromosome (BAC) and a method of producing and mutagenizing same.

The Amendments to the Claims

Claim 36 has been amended to recite that the host cell does not contain any herpes virus genes or herpes virus proteins. This amendment is supported by the specification at, e.g., page 3, lines 19-22, page 7, lines 3-8, Example 6, and Example 9. Accordingly, no new matter has been added by way of this amendment.

The Office Action

Claims 36, 37, 40, 42, 48, 51, 54, 57, 58, and 64-66 remain rejected under 35 U.S.C. § 102(b) as allegedly anticipated by Messerle et al., *J. Mol. Med.*, 74: B8 (1996) (“the Messerle reference”). Claims 41, 43, 44, 45-47, 49, 50, 52, 53, 55, 56, 59, 60-63, and 67-70 remain rejected under 35 U.S.C. § 103 as allegedly unpatentable over the Messerle reference alone or in combination with one or more of the following secondary references: Tomkinson et al., *J. Virol.*, 67: 7298-7306 (1993) (“the Tomkinson reference”), Ehtisham et al., *J. Virol.*, 67: 5247-5252 (1993) (“the Ehtisham reference”), Gage et al., *J. Virol.*, 66: 5509-5515 (1992) (“the Gage reference”), Roizman et al., *Science*, 229: 1208-1214 (1985) (“the Roizman reference”), Chen et al., *Mol. Cell. Biol.*, 7: 2745-2752 (1987) (“the Chen reference”), and Luckow et al., *J. Virol.*, 67: 4566-4579 (1993) (“the Luckow reference”). Reconsideration of these rejections is respectfully requested.

Examiner Interview

Applicants thank Examiner Sajjadi and his supervisor Joseph Woitach for the courtesy extended to their representative, Melissa E. Kolom, during the telephonic interview held on September 18, 2008. The matters discussed during the interview are substantially as set forth herein.

Discussion of Rejection Under 35 U.S.C. § 102

Claims 36, 37, 40, 42, 48, 51, 54, 57, 58, and 64-66 have been rejected under Section 102(b) as allegedly anticipated by the Messerle reference. This rejection is traversed for the reasons set forth below.

The Office Action alleges that the term “host cell” is not defined in the specification so as to exclude cells comprising genes that complement for deficiencies in the herpes virus genome present on the BAC. The Messerle reference discloses transfecting eukaryotic cells with two BAC/MCMV hybrid plasmids, which complement for each other to produce an infectious herpes virus particle. The Office Action contends that, because the eukaryotic cells disclosed in the Messerle reference contain herpes virus genomic sequences which complement for deficiencies in each respective BAC/MCMV plasmid, the Messerle reference reads on claim 36.

Claim 36, as amended, is directed to a BAC containing bacterial nucleic acid sequences and an infectious herpes virus genomic sequence larger than 100 kb, wherein the BAC contains all genes that are essential for the generation of an infectious herpes virus in a host cell, and wherein the host cell does not contain any herpes virus genes. The Messerle reference does not disclose the subject matter of the rejected claims. In this respect, the Messerle reference does not disclose a BAC containing all genes essential for the generation of an infectious herpes virus in a host cell, wherein the host cell does not contain any herpes virus genes or herpes virus proteins.

Thus, the Messerle reference does not disclose the subject matter of claims 36, 37, 40, 42, 48, 51, 54, 57, 58, and 64-66. Accordingly, the rejection under Section 102(b) should be withdrawn.

Discussion of Rejections Under 35 U.S.C. § 103


Claims 41, 43, 44, 45-47, 49, 50, 52, 53, 55, 56, 59, 60-63, and 67-70 have been rejected under Section 103 as allegedly unpatentable over the Messerle reference alone or in combination with one or more secondary references. This rejection is traversed for the reasons set forth below.

Claims 41, 43, 44, 45-47, 49, 50, 52, 53, 55, 56, 59, 60-63, and 67-70 directly or indirectly depend from claim 36. As discussed above, the Messerle reference does not disclose or suggest the subject matter of claim 36. As a result, the Messerle reference does not disclose or suggest the subject matter of claims 41, 43, 44, 45-47, 49, 50, 52, 53, 55, 56, 59, 60-63, or 67-70. None of the secondary references cited by the Office Action compensates for the deficiencies of the Messerle reference. In this respect, none of the Tomkinson, Ehtisham, Gage, Roizman, Chen, or Luckow references discloses or suggests a BAC containing all genes essential for the generation of an infectious herpes virus in a host cell, wherein the host cell does not contain any herpes virus genes or herpes virus proteins. Accordingly, the Section 103 rejection should be withdrawn.

Conclusion

Applicants respectfully submit that the patent application is in condition for allowance. If, in the opinion of the Examiner, a telephone conference would expedite the prosecution of the subject application, the Examiner is invited to call the undersigned agent.

Respectfully submitted,



Melissa E. Kolom, Reg. No. 51,860
LEYDIG, VOIT & MAYER, LTD.
Two Prudential Plaza, Suite 4900
180 North Stetson Avenue
Chicago, Illinois 60601-6731
(312) 616-5600 (telephone)
(312) 616-5700 (facsimile)

Date: October 14, 2008